DETAILED NOTES ON ABBV-744 BRD4 INHIBITOR MECHANISM OF ACTION

In Segment A, contributors will get diverse doses and schedules of oral ABBV-744 tablet to identify Protected dosing routine. Extra participants will be enrolled within the determined monotherapy dosign program. In Segment B, participants will get oral ruxolitinib and ABBV-744 will be offered as "insert-on" therapy. In Segment C, contributors will